Last reviewed · How we verify

NCT03795116

Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention

Completed Phase 2 Results posted Last updated 1 June 2022
What this trial tests

Phase 2 trial testing LED-RL phototherapy in Fibrosis in 30 participants. Completed in 26 October 2020.

Timeline
18 March 2019
Primary endpoint
26 October 2020
26 October 2020

Quick facts

Lead sponsorState University of New York - Downstate Medical Center
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment30
Start date18 March 2019
Primary completion26 October 2020
Estimated completion26 October 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

State University of New York - Downstate Medical Center

Who can join

Eligibility, any sex, with Fibrosis or Skin Scarring. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Scar Pliability Between the Treated and Control Incision Sites as Measured by Skin Induration at Three Follow-up Time Points Compared to Baseline Primary · Baseline assessment was completed on post-operative day 5, before LED-RL or mock phototherapy treatment. Follow-up visits were scheduled on approximately post-operative day 30 (1 month), post-operative 90 (3 months), and post-operative day 180 (6 months).

The SkinFibroMeter, a non-invasive indentation instrument, will be used to evaluate the induration of the skin and subcutaneous tissue (i.e., hardness) of the LED-RL-treated scar versus the untreated scar. Skin induration is measured in Newtons (N).

Baseline
GroupValue95% CI
LED-RL Phototherapy Group 1.08.04 – .14
Mock Irradiation Group 1.05.02 – .08
LED-RL Phototherapy Group 2.09.03 – .13
Mock Irradiation Group 2.06.04 – .08
LED-RL Phototherapy Group 3.06.04 – .07
Mock Irradiation Group 3.07.02 – .08
1 month
GroupValue95% CI
LED-RL Phototherapy Group 1.05.04 – .08
Mock Irradiation Group 1.04.03 – .08
LED-RL Phototherapy Group 2.06.04 – .08
Mock Irradiation Group 2.05.03 – .12
LED-RL Phototherapy Group 3.05.03 – .08
Mock Irradiation Group 3.04.02 – .04
3 months
GroupValue95% CI
LED-RL Phototherapy Group 1.03.03 – .06
Mock Irradiation Group 1.04.02 – .05
LED-RL Phototherapy Group 2.04.03 – .07
Mock Irradiation Group 2.04.04 – .07
LED-RL Phototherapy Group 3.05.04 – .06
Mock Irradiation Group 3.06.04 – .08
6 months
GroupValue95% CI
LED-RL Phototherapy Group 1.03.02 – .03
Mock Irradiation Group 1.03.02 – .03
LED-RL Phototherapy Group 2.02.02 – .03
Mock Irradiation Group 2.03.03 – .03
LED-RL Phototherapy Group 3.03.02 – .03
Mock Irradiation Group 3.02.02 – .03
Observer Scar Assessment Scale Secondary · Baseline assessment was completed on post-operative day 5, before LED-RL or mock phototherapy treatment. Follow-up visits were scheduled on approximately post-operative day 30 (1 month), post-operative 90 (3 months), and post-operative day 180 (6 months).

The scale consists of six items rated from 1 to 10, where 1 is "normal skin" and 10 is the "worst imaginable scar". The observer (i.e., investigator) evaluates scar vascularity, pigmentation, thickness, relief, pliability, and surface area. The scores of each of the six items are summed for a total score (range 6 to 60).

Baseline
GroupValue95% CI
LED-RL Phototherapy Group 116.514.0 – 20.0
Mock Irradiation Group 116.515.0 – 21.0
LED-RL Phototherapy Group 219.016.0 – 21.0
Mock Irradiation Group 214.013.0 – 17.0
LED-RL Phototherapy Group 318.016.0 – 19.0
Mock Irradiation Group 316.515.0 – 20.0
1 month
GroupValue95% CI
LED-RL Phototherapy Group 117.015.0 – 18.0
Mock Irradiation Group 117.014.0 – 19.0
LED-RL Phototherapy Group 213.011.0 – 16.0
Mock Irradiation Group 217.511.0 – 19.0
LED-RL Phototherapy Group 319.017.0 – 21.0
Mock Irradiation Group 313.012.0 – 15.0
3 months
GroupValue95% CI
LED-RL Phototherapy Group 112.511.5 – 17.0
Mock Irradiation Group 115.014.0 – 16.0
LED-RL Phototherapy Group 212.011.0 – 18.0
Mock Irradiation Group 214.09.0 – 18.0
LED-RL Phototherapy Group 315.012.0 – 19.0
Mock Irradiation Group 313.012.0 – 14.0
6 months
GroupValue95% CI
LED-RL Phototherapy Group 19.08.0 – 18.0
Mock Irradiation Group 112.511.0 – 14.0
LED-RL Phototherapy Group 28.08.0 – 20.0
Mock Irradiation Group 214.012.0 – 16.0
LED-RL Phototherapy Group 313.010.0 – 15.0
Mock Irradiation Group 312.08.0 – 19.0
Dermal Collagen Concentration Secondary · Baseline assessment was completed on post-operative day 5, before LED-RL or mock phototherapy treatment. Follow-up visits were scheduled on approximately post-operative day 30 (1 month), post-operative 90 (3 months), and post-operative day 180 (6 months).

A non-invasive, handheld diffuse reflectance probe will be used to measure collagen concentration in the dermis at each incision site. The scale ranges from 10 to 99 and the collagen measurement corresponds to the half of the optical scattering coefficient of the dermis.

Baseline
GroupValue95% CI
LED-RL Phototherapy Group 148.741.0 – 59.5
Mock Irradiation Group 152.037.0 – 62.6
LED-RL Phototherapy Group 251.034.0 – 59.0
Mock Irradiation Group 250.542.0 – 62.0
LED-RL Phototherapy Group 347.739.3 – 62.0
Mock Irradiation Group 352.546.0 – 62.0
1 month
GroupValue95% CI
LED-RL Phototherapy Group 160.350.0 – 62.0
Mock Irradiation Group 147.029.3 – 56.3
LED-RL Phototherapy Group 250.744.7 – 58.0
Mock Irradiation Group 255.243.7 – 60.0
LED-RL Phototherapy Group 352.742.3 – 60.7
Mock Irradiation Group 357.048.3 – 60.3
3 months
GroupValue95% CI
LED-RL Phototherapy Group 157.547.8 – 60.3
Mock Irradiation Group 157.455.5 – 61.5
LED-RL Phototherapy Group 258.355.0 – 60.7
Mock Irradiation Group 257.354.7 – 58.0
LED-RL Phototherapy Group 358.748.0 – 59.6
Mock Irradiation Group 358.755.6 – 62.0
6 months
GroupValue95% CI
LED-RL Phototherapy Group 157.055.3 – 58.7
Mock Irradiation Group 156.553.0 – 60.3
LED-RL Phototherapy Group 260.056.0 – 61.7
Mock Irradiation Group 261.054.7 – 61.3
LED-RL Phototherapy Group 356.750.3 – 57.0
Mock Irradiation Group 359.356.7 – 61.3
Dermal Water Concentration Secondary · Baseline assessment was completed on post-operative day 5, before LED-RL or mock phototherapy treatment. Follow-up visits were scheduled on approximately post-operative day 30 (1 month), post-operative 90 (3 months), and post-operative day 180 (6 months).

A non-invasive, handheld diffuse reflectance probe will be used to measure water concentration in the dermis at each incision site. Infrared light is emitted at different wavelengths to retrieve the scattering and the absorption coefficients of the dermis. The more water, the less reflectance. Concentration ranges from 40% to 85%.

Baseline
GroupValue95% CI
LED-RL Phototherapy Group 163.060.0 – 64.3
Mock Irradiation Group 165.362.3 – 66.0
LED-RL Phototherapy Group 260.758.7 – 62.0
Mock Irradiation Group 262.760.0 – 66.0
LED-RL Phototherapy Group 363.262.0 – 67.7
Mock Irradiation Group 366.263.0 – 68.0
1 month
GroupValue95% CI
LED-RL Phototherapy Group 164.062.0 – 65.0
Mock Irradiation Group 162.361.3 – 63.3
LED-RL Phototherapy Group 260.258.3 – 61.7
Mock Irradiation Group 262.358.3 – 63.3
LED-RL Phototherapy Group 360.658.7 – 62.7
Mock Irradiation Group 364.060.0 – 65.0
3 months
GroupValue95% CI
LED-RL Phototherapy Group 163.059.7 – 67.8
Mock Irradiation Group 161.459.0 – 67.3
LED-RL Phototherapy Group 263.059.7 – 66.3
Mock Irradiation Group 260.759.3 – 62.3
LED-RL Phototherapy Group 361.760.6 – 63.3
Mock Irradiation Group 362.057.0 – 67.6
6 months
GroupValue95% CI
LED-RL Phototherapy Group 162.559.0 – 64.3
Mock Irradiation Group 161.259.7 – 64.0
LED-RL Phototherapy Group 263.762.3 – 68.3
Mock Irradiation Group 263.062.7 – 64.7
LED-RL Phototherapy Group 362.061.3 – 62.3
Mock Irradiation Group 364.061.3 – 64.7
Number of Participants Experiencing Adverse Events in Each Treatment Group Secondary · From first LED-RL and mock phototherapy treatment session on post-operative day 5 until final follow-up visit on post-operative day 180 (6 month follow-up).

Subjects will be provided with a daily diary to record any adverse events experienced during the three-week intervention period. Treatment sessions will be monitored closely for the occurrence of any safety issues or adverse events, as reported by the subject or observed by the clinical research team. At each follow up visit, patients will be asked about adverse effects.

GroupValue95% CI
LED-RL Phototherapy Group 10
Mock Irradiation Group 10
LED-RL Phototherapy Group 21
Mock Irradiation Group 20
LED-RL Phototherapy Group 31
Mock Irradiation Group 30
LED-RL Phototherapy Group 10
Mock Irradiation Group 10
LED-RL Phototherapy Group 20
Mock Irradiation Group 20
LED-RL Phototherapy Group 31
Mock Irradiation Group 30
LED-RL Phototherapy Group 110
Mock Irradiation Group 110
LED-RL Phototherapy Group 29
Mock Irradiation Group 210
LED-RL Phototherapy Group 38
Mock Irradiation Group 310
Patient Scar Assessment Scale Secondary · Baseline assessment was completed on post-operative day 5, before LED-RL or mock phototherapy treatment. Follow-up visits were scheduled on approximately post-operative day 30 (1 month), post-operative 90 (3 months), and post-operative day 180 (6 months).

The scale consists of six items rated from 1 to 10, where 1 is "normal skin" and 10 is the "worst imaginable scar". The patient assesses pain, itching, color, stiffness, thickness, and irregularity. The scores of each of the six items are summed for a total score (range 6 to 60).

Baseline
GroupValue95% CI
LED-RL Phototherapy Group 136.027.0 – 42.0
Mock Irradiation Group 137.024.0 – 41.0
LED-RL Phototherapy Group 232.023.0 – 34.0
Mock Irradiation Group 230.527.0 – 32.0
LED-RL Phototherapy Group 326.521.0 – 33.0
Mock Irradiation Group 328.524.0 – 48.0
1 month
GroupValue95% CI
LED-RL Phototherapy Group 125.021.0 – 34.0
Mock Irradiation Group 125.019.0 – 34.0
LED-RL Phototherapy Group 224.019.0 – 29.0
Mock Irradiation Group 223.518.0 – 30.0
LED-RL Phototherapy Group 317.013.0 – 37.0
Mock Irradiation Group 326.013.0 – 37.0
3 months
GroupValue95% CI
LED-RL Phototherapy Group 112.512.0 – 18.0
Mock Irradiation Group 115.012.0 – 25.5
LED-RL Phototherapy Group 218.017.0 – 26.0
Mock Irradiation Group 221.018.0 – 26.0
LED-RL Phototherapy Group 317.514.0 – 32.0
Mock Irradiation Group 320.012.0 – 26.0
6 months
GroupValue95% CI
LED-RL Phototherapy Group 112.07.0 – 17.0
Mock Irradiation Group 110.510.0 – 12.0
LED-RL Phototherapy Group 223.012.0 – 28.0
Mock Irradiation Group 218.016.0 – 24.0
LED-RL Phototherapy Group 313.010.0 – 25.0
Mock Irradiation Group 317.011.0 – 26.0

Adverse events — posted to ClinicalTrials.gov

Time frame: LED-RL and mock phototherapy treatment sessions were monitored for the occurrence of safety concerns and AEs, as reported by the patient or observed by the research team. Patients recorded AEs during the three-week LED-RL and mock phototherapy treatment period in a home diary. At each visit, participants were asked about AEs.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

LED-RL Phototherapy Group 1
Serious: 0/10 (0%)
Deaths: 0/10
Mock Irradiation Group 1
Serious: 0/10 (0%)
Deaths: 0/10
LED-RL Phototherapy Group 2
Serious: 0/10 (0%)
Deaths: 0/10
Mock Irradiation Group 2
Serious: 0/10 (0%)
Deaths: 0/10
LED-RL Phototherapy Group 3
Serious: 0/10 (0%)
Deaths: 0/10
Mock Irradiation Group 3
Serious: 0/10 (0%)
Deaths: 0/10
Other adverse events (2 terms — click to expand)

ReactionSystemLED-RL Phototherapy Group 1Mock Irradiation Group 1LED-RL Phototherapy Group 2Mock Irradiation Group 2LED-RL Phototherapy Group 3Mock Irradiation Group 3
Localized BullaSkin and subcutaneous tissue disorders
Localized Facial SwellingSkin and subcutaneous tissue disorders

Data from ClinicalTrials.gov NCT03795116 adverse events section.

Sponsor's own description

Skin scarring (fibrosis) is a common complication in the wound healing process and remains a therapeutic challenge. Scar formation often occurs following injury to the skin such as surgery, trauma, and burns. The goal of this study is to evaluate the safety and efficacy of visible red light as a modality to reduce skin scarring after mini-facelift surgery. Based on laboratory data, light emitting diode-red light (LED-RL) phototherapy may lessen post-surgical skin fibrosis clinically.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Light emitting diode-red light for reduction of post-surgical scarring: Results from a dose-ranging, split-face, randomized controlled trial.
    Kurtti A, Nguyen JK, Weedon J, Mamalis A, et al · · 2021 · cited 11× · PMID 33788987 · DOI 10.1002/jbio.202100073
  2. A dose-ranging, parallel group, split-face, single-blind phase II study of light emitting diode-red light (LED-RL) for skin scarring prevention: study protocol for a randomized controlled trial.
    Nguyen JK, Weedon J, Jakus J, Heilman E, et al · · 2019 · cited 10× · PMID 31307501 · DOI 10.1186/s13063-019-3546-6
  3. High-fluence light emitting diode-red light inhibits cell cycle progression in human dermal fibroblasts.
    Masub N, Austin E, Huang A, Jagdeo J. · · 2021 · cited 7× · PMID 33038043 · DOI 10.1002/jbio.202000359
  4. Current State of Clinical Trials for Keloid Management: An Analysis of Trials Registered on ClinicalTrials.gov.
    Park S, Li D, Guo L, Xu X. · · 2026 · PMID 42077711 · DOI 10.7759/cureus.106243

Verify or expand the search:

Other recruiting trials for Fibrosis

Currently open trials in the same condition.

Other State University of New York - Downstate Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03795116.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing